Patents by Inventor Andreas BEILHACK

Andreas BEILHACK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FC?R-independent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with FC?R-independent agonistic activity; TRAAFFIAA)
    Patent number: 12715928
    Abstract: The present invention relates to tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FcyR-independent agonistic activity, and to compositions and methods related thereto.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 25, 2026
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Andreas Beilhack, Juliane Medler, Johannes Nelke, Harald Wajant
  • ANTI-CD40 ANTIBODY CONSTRUCTS WITH HIGH INTRINSIC AGONISM
    Publication number: 20260092124
    Abstract: The present invention relates to oligomeric and oligovalent anti-CD40 antibody variants displaying high intrinsic, thus Fc?R-independent, agonistic activity. The invention more specifically relates to tetra-, penta-, hexa-, hepta-, octa-, nona-, deca- and docevalent or even higher valency antibody constructs with Fc?R-independent activity composed of CD40-specific Fab- and/or scFv domains and/or sdAb domains and an dimeric, trimeric, tetrameric oligomerization scaffold preferentially Fc, IgG molecule or trimerization domain of TNC. The invention also relates to the enforced oligomerization of several anti-CD40 IgG molecules, that can be achieved in a stoichiometric fashion by genetic engineering, that confers strong Fc?R-independent agonism, and to the fact that the idiotype of the anti-CD40 antibody has no major effect on the autonomous agonism of oligovalent anti-CD40 variants.
    Type: Application
    Filed: September 22, 2023
    Publication date: April 2, 2026
    Inventors: Harald Wajant, Isabell Lang, Daniela Siegmund, Andreas Beilhack
  • ANTIBODY-BASED SOLUBLE AND MEMBRANE-BOUND TWEAK MIMICKING AGONISTS WITH FCYR-INDEPENDENT ACTIVITY
    Publication number: 20250277046
    Abstract: The present invention relates to multivalent anti-Fn14 antibody constructs that show memTWEAK-mimicking agonism. The invention more specifically relates to tetra-, hexa- and octavalent antibody constructs composed of Fn14-specific Fab- and scFv domains with Fc?R-independent activity. The invention also relates to methods of producing such multivalent anti-Fn14 antibody constructs, pharmaceutical compositions comprising the same, as well as their uses for treating cancer.
    Type: Application
    Filed: May 25, 2023
    Publication date: September 4, 2025
    Inventors: Harald Wajant, Olena Zaitseva, Christoph Otto, Andreas Beilhack
  • Novel TNFR2 Binding Molecules
    Publication number: 20240190983
    Abstract: The present invention provides a binding molecule that specifically binds TNFR2, but not TNFR1. Preferably the binding molecule is an Fc?R-independent agonist of TNFR2 and more preferably has a valency of at least two for binding TNFR2. The binding molecules have a variety of uses including diagnostic and therapeutic. The ability of the binding molecules to be able to modulate immune responses means that they are particularly suited for treating autoimmune diseases, or inflammatory conditions.
    Type: Application
    Filed: April 1, 2022
    Publication date: June 13, 2024
    Inventors: Harald Wajant, Andreas Beilhack, Juliane Medler, Tim Steinfatt, Luc Van Rompaey
  • TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
    Publication number: 20210079106
    Abstract: The present invention relates to tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with FcyR-independent agonistic activity, and to compositions and methods related thereto.
    Type: Application
    Filed: December 20, 2018
    Publication date: March 18, 2021
    Inventors: Andreas Beilhack, Juliane Kums, Johannes Nelke, Harald Wajant
  • Galactose oxidase treatment of dendritic cells to improve their immunogenicity
    Patent number: 10253294
    Abstract: The present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 9, 2019
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Marion Heuer, Manfred Lutz, Andreas Beilhack
  • Galactose Oxidase Treatment of Dendritic Cells to Improve their Immunogenicity
    Publication number: 20160312184
    Abstract: The present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.
    Type: Application
    Filed: December 18, 2014
    Publication date: October 27, 2016
    Inventors: Marion HEUER, Manfred LUTZ, Andreas BEILHACK